Select Page

ANA Investigates Updates in Autoimmune Encephalitis, part 1, diagnostics

In this episode, Dr. Adeline Goss interviews Dr. Andrew McKeon on updates on diagnostics for part one of a two-part series on autoimmune encephalitis. Series 3, Episode 8. Featuring: Guest: Andrew McKeon, M.B., B.Ch., M.D., Mayo Clinic College of Medicine and Science

ANA Investigates Updates in Autoimmune Encephalitis, part 2, therapeutics

Advances in the treatment of autoimmune encephalitis. Treating these conditions has traditionally been practitioner-dependent, and currently, no FDA-approved therapies exist. But that’s beginning to change. Series 3, Episode 9. Featuring: Guest: Dr. Maarten Titulaer, Erasmus MC University Medical Center

Paraneoplastic neurological syndromes: a practical approach to diagnosis and management

Dr Amy Ross Russell, Neurology, University Hospital Southampton NHS Foundation Trust, interviews Dr Sophie Binks and Professor Sarosh Irani, from the Oxford Autoimmune Neurology Group, about their recent paper about a practical approach to diagnosis and management of paraneoplastic neurological syndromes.
Read the latest Editor’s Choice paper on the Practical Neurology website (pn.bmj.com/content/22/1/19) and the February print issue of the journal.

Autoimmune Axonal Testing: Divyanshu (Div) Dubey, M.B.B.S.

ANSWERS FROM THE LAB • EPISODE 115

Divyanshu Dubey, M.B.B.S., discusses the serological panel, which uses multiple methodologies to detect for nine distinct antibodies.

“All of the antibodies included in this panel are of significant relevance to patients with neuropathy,” Dr. Dubey says. “They not only provide information about the underlying etiology of neuropathy, they also point us towards if there’s an underlying cancer. They help us with having discussions with patients about the natural history of the disease and coming up with the best treatment regimen.”

The phenotype-specific approach to antibody evaluation is an improvement on previous approaches.  All relevant antibodies are included, not just those associated with cancer, and an improved methodology for several important tests helps improve specificity.

Dr. Carr- Diagnosing Anti-NMDA Receptor Encephalitis

This Best Case Ever is about Anti-NMDA Receptor Encephalitis, a diagnosis that was only discovered in 2005, and has only recently been recognized by the Emergency Medicine community.  Anti-NMDA Receptor Encephalitis may mimic a first presentation of schizophrenia or Neuraleptic Malignant Syndrome.  It may present with seizure, altered mental status, autonomic instability or movement disorder in the absence of drug exposure. When you are faced with any of these presentations and no other diagnosis seems to fit, do an LP and send the CSF for anti-NMDA receptor antibodies. The time-sensitive treatment is IVIG and steroids.  Anti-NMDA receptor Encephalitis is a must know diagnosis for all emergency medicine practitioners. 

Practice Current: Autoimmune Encephalitis & the Role of Antibody Testing

Dr. Luca Bartolini discusses autoimmune encephalitis and the role of antibody testing based on a Practice Current survey run between November 2017 and May 2018.

Criteria of diagnosis

Treating AE

Invisible Illness: The Struggle To Be Recognized And Treated For AE

Co-founder Tabitha Andrews Orth and IAES member Kelly McCabe discuss how their life saving treatments have been denied and the struggle to raise awareness of AE and receive treatment for this reversible condition. 

Genetic testing

Genetic testing in early onset epileptic encephalopathies

Surviving AE

In 2014, Jake Pickard watched doctors try to save his girlfriend’s brain. What happened would dramatically change their relationship and their lives. Elizabeth Nakano headed to Eastham to interview them about the aftermath.

Practice Current: Autoimmune Encephalitis & the Role of Antibody Testing

Dr. Luca Bartolini discusses autoimmune encephalitis and the role of antibody testing based on a Practice Current survey run between November 2017 and May 2018.

Rituximab

In the First Segment, Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.

Our website is not a substitute for independent professional medical advice. Nothing contained on our website is intended to be used as medical advice. No content is intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional's advice. Although THE INTERNATIONAL AUTOIMMUNE ENCEPHALITIS SOCIETY  provides a great deal of information about AUTOIMMUNE ENCEPHALITIS, all content is provided for informational purposes only. The International Autoimmune Encephalitis Society  cannot provide medical advice.


International Autoimmune Encephalitis Society is a charitable non-profit 501(c)(3) organization founded in 2016 by Tabitha Andrews Orth, Gene Desotell and Anji Hogan-Fesler. Tax ID# 81-3752344. Donations raised directly supports research, patients, families and caregivers impacted by autoimmune encephalitis and to educating healthcare communities around the world. Financial statement will be made available upon request.

CONTACT US


352-527-2470

IAES@AUTOIMMUNE-ENCEPHALITIS.ORG

Autoimmune Encephalitis Trivia Playing Cards

Translate »